tetano
Editor, Senior Moderator
Front Immunol
. 2022 Nov 21;13:1035571.
doi: 10.3389/fimmu.2022.1035571. eCollection 2022.
SARS-COV-2 infections in inborn errors of immunity: A single center study
Kimberley Cousins[SUP] 1 [/SUP], Nicholas DeFelice[SUP] 2 3 4 [/SUP], Stephanie Jeong[SUP] 1 [/SUP], Jin Feng[SUP] 1 [/SUP], Ashley Sang Eun Lee[SUP] 1 [/SUP], Karina Rotella[SUP] 1 [/SUP], David Sanchez[SUP] 1 [/SUP], Faris Jaber[SUP] 1 [/SUP], Shradha Agarwal[SUP] 1 [/SUP], Hsi-En Ho[SUP] 1 [/SUP], Charlotte Cunningham-Rundles[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). One of the main topics of conversation in these past months in the world of immunology has been the issue of how patients with immune defects will fare if they contract this infection. To date there has been limited data on larger cohorts of patients with Inborn Errors of Immunity (IEI) diagnosed with COVID-19. Here, we review the data of COVID-19 infections in a single center cohort of 113 patients from the Mount Sinai Immunodeficiency program, who had 132 infections between January 2020 and June 2022. This included 56 males and 57 females, age range 2 - 84 (median 42). The mortality rate was 3%. Comparison between admitted patients revealed a significantly increased risk of hospitalization amongst the unvaccinated patients, 4% vaccinated vs 40% unvaccinated; odds ratio 15.0 (95% CI 4.2 - 53.4; p <0.00001). Additionally, COVID anti-spike antibody levels, determined in 36 of these patients post vaccination and before infection, were highly variable.
Keywords: X-linked agammaglobulinemia (XLA); common variable immunodeficiency (CVID); coronavirus disease 2019 (COVID-19); covid vaccination; inborn errors of immunity (IEI); monoclonal therapy; primary immunodeficiency (PID); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2022 Nov 21;13:1035571.
doi: 10.3389/fimmu.2022.1035571. eCollection 2022.
SARS-COV-2 infections in inborn errors of immunity: A single center study
Kimberley Cousins[SUP] 1 [/SUP], Nicholas DeFelice[SUP] 2 3 4 [/SUP], Stephanie Jeong[SUP] 1 [/SUP], Jin Feng[SUP] 1 [/SUP], Ashley Sang Eun Lee[SUP] 1 [/SUP], Karina Rotella[SUP] 1 [/SUP], David Sanchez[SUP] 1 [/SUP], Faris Jaber[SUP] 1 [/SUP], Shradha Agarwal[SUP] 1 [/SUP], Hsi-En Ho[SUP] 1 [/SUP], Charlotte Cunningham-Rundles[SUP] 1 [/SUP]
Affiliations
- PMID: 36479106
- PMCID: PMC9720892
- DOI: 10.3389/fimmu.2022.1035571
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). One of the main topics of conversation in these past months in the world of immunology has been the issue of how patients with immune defects will fare if they contract this infection. To date there has been limited data on larger cohorts of patients with Inborn Errors of Immunity (IEI) diagnosed with COVID-19. Here, we review the data of COVID-19 infections in a single center cohort of 113 patients from the Mount Sinai Immunodeficiency program, who had 132 infections between January 2020 and June 2022. This included 56 males and 57 females, age range 2 - 84 (median 42). The mortality rate was 3%. Comparison between admitted patients revealed a significantly increased risk of hospitalization amongst the unvaccinated patients, 4% vaccinated vs 40% unvaccinated; odds ratio 15.0 (95% CI 4.2 - 53.4; p <0.00001). Additionally, COVID anti-spike antibody levels, determined in 36 of these patients post vaccination and before infection, were highly variable.
Keywords: X-linked agammaglobulinemia (XLA); common variable immunodeficiency (CVID); coronavirus disease 2019 (COVID-19); covid vaccination; inborn errors of immunity (IEI); monoclonal therapy; primary immunodeficiency (PID); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).